Back to Sites

Gaborone CRS

Site Number

12701

Address

Gaborone Prevention/Treatment Trials CRS
Princess Marina Hospital
Plot 1836, North Ring Road
Gaborone,
Botswana

IMPAACT Members at this Site

Unoda Chakalisa CRS Coordinator

Tebogo Kakhu CRS Coordinator

Anthony Ogwu CRS Leader

Ayotunde Omoz-Oarhe CRS Leader

Tendani Gaolathe CRS Staff

Loeto Mazhani CRS Staff

Mompati Mmalane CRS Staff

Sylvester Musa-Aisien CRS Staff

Gaerolwe Masheto CTU Coordinator

Shahin Lockman CTU Principal Investigator

Joseph Makhema CTU Principal Investigator

Sue Welsch DAIDS PO

Sikhulile Moyo Laboratory Director

Terence Mohammed Laboratory Manager/Supervisor

Lesedi Tirelo Laboratory QA/QC Coordinator

Motswedi Anderson Laboratory Technician/Technologist

Rufaro Mangwarara Pharmacist

Yvonne Mugodi Pharmacist

Tshepho Frank Pharmacy Supervisor

Urunduruka Munamava QA/QC Coordinator

Tumalano Sekoto Regulatory Coordinator

Taolo Modise Research Nurse

Mpho Raesi Research Nurse

Aida Asmelash Staff

Gaerolwe Masheto Staff

Tebogo Mokotedi Staff

Akeem Salawu Staff

Dichaba Siane Staff

Ponego Ponatshego Study Coordinator

Mpho Raesi Study Coordinator

Studies at this Site

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

P1026S: PK in Pregnancy

DAIDS Number

Therapeutics

Research Area

Treatment

Study Status

Closed to Follow Up

P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity

DAIDS Number

10495

Research Area

Treatment

Study Status

Concluded

P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers

DAIDS Number

10638

Research Area

Complications & Comorbidities

Study Status

Concluded

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Therapeutics

IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

DAIDS Number

20735

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Brain and Mental Health

Study Status

Closed to Accrual

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed